The HeartFlow ADVANCE Registry: A step forward but ways to go Information on coronary physiology is increasingly being implemented in clinical routine to inform treatment decisions in cardiac catheter suites. Coronary stenosis severity and lesion-ischaemia can be assessed invasively based on the myocardial fractional flow reserve (FFR). Using a dedicated coronary 'Pressure-Wire', resting distal coronary pressure can be measured and its ratio to aortic pressure [Pd/Pa] during hyperaemia provides FFR-values with an ischaemic threshold defined as < _0.80.
computational fluid dynamics (CFD) processed using either off-site or on-site computers, assessment of FFR at any point within the coronary system has been shown to be feasible using various computer platforms. [2] [3] [4] [5] [6] [7] [8] [9] [10] CFD has been in use for nearly three decades and refers to the use of a computer to solve the Navier-Stokes equations, which are basic equations governing the motion of a viscous, heat-conducting fluid. 11 From a clinical stand point, the concept is extremely attractive. In the best of cases, coronary CT-angiography (CTA) can thus deliver information regarding coronary anatomy, coronary atherosclerosis, and the functional significance of lesions, an almost perfect basis for decisionmaking in patients with suspected coronary artery disease (CAD). So far, the accuracy of off-site FFR CT has been evaluated in three large clinical studies by direct comparison to invasively measured FFR. 2, 5, 6 'HeartFlow NXT', the most recent trial, was a prospective multicenter study that included 254 patients referred for clinically indicated invasive coronary angiography. 6 In this study, the majority of patients (235 patients) had intermediate coronary stenosis which introduced a relevant, but often neglected bias to the study's clinical main result: In the studied cohort, FFR CT showed a higher specificity for detecting ischaemia-causing lesions than coronary CTA alone. Researchers involved in FFR CT have since been striving to provide data to prove that the addition of FFR CT to coronary CTA alone results in fewer inadequate coronary angiograms, potentially fewer revascularizations, and equal, if not improved, patient outcome. This is a laudable undertaking, and one that many other imaging tests are missing. It would help counter the frequent voices that 'coronary CT angiography results in too many unnecessary angiograms and revascularizations'-even though these voices have become a bit softer since in the recent SCOT-HEART trial, the 5-year revascularization rate in patients undergoing coronary CT angiography was equal to those who were managed without CT. 12 The HeartFlow ADVANCE Registry is a prospective real-world registry that enrolled patients from 38 countries between 2015 and 2017. 13 The aim of this registry was to determine the impact of using CT anatomic data with or without additional FFR CT data on downstream invasive coronary angiography, revascularization, and major adverse cardiovascular events (MACE) on follow-up. Over a period of 2 years, a total of 5083 patients with symptoms suspicious of CAD and with atherosclerosis defined as stenosis >30% were enrolled. Their demographics, symptom status, coronary CT angiography and FFR CT findings, treatment plans, and 90 day outcomes were recorded. For every site, clinicians were asked to first document a treatment strategy based on anatomic CT findings alone. The decision to further obtain FFR CT data was left to the discretion of each participating site with investigators encouraged to obtain FFR CT in stenoses ranging between 30% and 90%. After providing FFR CT data, site investigators were asked to document a second treatment plan after knowledge of FFR CT data. In the same way, a core lab blinded to patient symptoms and clinical data reported treatment plans based on anatomic CT information alone and after knowing FFR CT data. The primary endpoint of this registry was the reclassification between the core-lab management plans based on coronary CT angiography alone and based on coronary CT angiography plus FFR CT . Out of 5083 patients, FFR CT was submitted in 96.2% of the patients. The primary endpoint, re-classification of treatment plans based on FFR CT as compared with coronary CTA alone, occurred in 66.9% [confidence interval (CI): 64.8-67.6] of patients. Some secondary endpoints included: incidence of invasive coronary angiography demonstrating absence of obstructive CAD; percutaneous and surgical revascularization rates; and 90 days survival free from all cause or MACE inclusive of myocardial infarction (MI), all-cause mortality or unplanned hospitalization for acute coronary syndrome leading to revascularization. 80 . Based on these results, the authors conclude that FFR CT modified the treatment recommendation in two-thirds of subjects as compared with CT angiography alone, was associated with fewer 'negative' invasive coronary angiograms, and predicted revascularization.
Although these data point to a safe short term outcome of patients with FFR CT > 0.8, several limitations concerning the conceptual design of this registry and the interpretation of the results have to be addressed. First, the primary endpoint of re-classification of treatment plan according to FFR CT data is subject to bias in many ways: Only CT studies with at least 30% stenosis were included, so the results do not apply to the large number of coronary CTA angiograms performed for clinical reasons which show complete absence or only minimal coronary atherosclerosis. Furthermore, with this study design, investigators both on-site and in the core lab will be very liberal to assign an 'invasive' management path based on coronary CTA alone, knowing that the 'parachute' of FFR CT will prevent that angiogram if it is not really necessary. Second, this was a very low-risk population with 60-70% of enrolled patients having either atypical symptoms or no symptoms at all. Third, the results of this registry-due to the absence of randomization-do not provide information whether re-classification of management pathways based on FFR CT data is the clinically sound decision as compared with coronary CTA alone (a limitation shared with the PLATFOM trial, which did not include a 'coronary CTA alone' arm 14 ) . It is reassuring and clinically useful to know that MACE did not occur in patients with FFR CT > 0.8, but it still remains unclear whether the same outcome would have been achieved if patients were managed according to CT coronary angiography alone. It is, in fact, surprising to see that vessels deemed as anatomically normal or with stenoses of 30% or less, yielded FFR CT results below 0.8 in a significant number of patients [e.g. out of 743 patients in whom the left anterior descending artery (LAD) was either normal or had a lesion <30%, the FFR CT value of the LAD was < _0.8 in 273 patients]. Accordingly, site investigators recommended medical treatment in almost 50% of subjects with an FFR CT <0.71. Clearly, for positive and potentially also for negative FFR CT values, various additional considerations seem to affect clinical decision-making. Lastly, for patients with FFR CT < _0.8, a hazard ratio of 19.75 for the occurrence of MACE with a confidence interval from 1.19 to 326 was reported which raises statistical concerns especially given the fact that that revascularization in a relatively low-risk cohort is not expected to affect outcome within 90 days.
In conclusion, assessment of haemodynamic significance of coronary artery stenosis using FFR CT is an interesting domain. The ADVANCE registry provides valuable insight on outcome safety of subjects with FFR >0.8, but needs to be interpreted with care and caution, given the sources of bias inherent to a registry design. We simply do not know whether we may have achieved very similar outcomes had coronary CT angiography been performed alone, potentially in connection with expert core-lab interpretation. 15 Furthermore, currently the clinically available solution for FFR CT can be obtained only through off-site services with the use of super-computers while on-site assessment is available as prototypes and mainly for research purposes. This contributes to less wide-spread use of the modality. Lastly, it still remains unclear whether the cut-off for FFR CT to define ischaemic lesions might be different than cut-off used for the invasive gold-standard. While ADVANCE is certainly a step in the right direction, the potential incremental value of FFR CT compared with coronary CT angiography alone can only be provided with bias-free randomization to diagnostic strata and longer-term outcome data.
